ارزیابی فعالیت ضد پارکینسونی آستاگزانتین در شرایط برون تنی ودرون تنی

نوع مقاله : مقاله پژوهشی

نویسندگان

1 دانشجوی فیزیولوژی جانوری گروه زیستشناسی، دانشکده علومزیستی، دانشگاه آزاد اسلامی‎واحد تهران شمال، تهران، ایران

2 استادیار گروه زیست شناسی، دانشکده علوم زیستی، دانشگاه آزاد اسلامی‎واحد تهران شمال، تهران، ایران (نویسنده مسئول)

3 دانشیار گروه فیزیولوژی دانشگاه علوم پزشکی قزوین، قزوین، ایران

4 استادیار گروه زیستشناسی، دانشکده علومزیستی، دانشگاه آزاد اسلامی‎واحد تهران شمال، تهران، ایران

5 استادیار گروه زیست شناسی دانشکده علوم، دانشگاه آزاد اسلامی‎واحد کرج، کرج ایران

چکیده

زمینه وهدف :التهاب و استرس اکسیداتیو در پاتوژنز بیماری پارکینسون نقش دارند. آستاگزانتی ندارای اثرات آنتی اکسیدانی ، ضد التهابی است و ممکن است برای درمان بیماری پارکینسونمفید باشد.در مطالعه حاضر ، ما اثرات مفیدآستاگزانتینرا در برابر سمیت 6-هیدروکسی دپامیندر مدل های حیوانی و سلولی بررسی کردیم.
مواد و روش ها : از موش نژاد NMRIاستفاده شد.پارکینسون با تزریق6-هیدروکسی دوپامینبه داخل جسم مخطط چپ ایجاد شد. موش های پارکینسونی به گروه شاهد و درمانی تقسیم شدند.گروه درمانی به مدت 28 روز آب یا آستاگزانتین (10،20و30 میلی گرم برکیلوگرم) را به صورت خوراکی دریافت کردند. فعالیت های رفتاری موش ها با آزمون چرخشی ناشی از آپومورفین تعیین شد. سلول های دوپامینرژیکSH-SY5Y به مدت 48 ساعت با آستاگزانتین(25/1، 5/2، 5، 10و20 میکرومول ) در حضور یا عدم حضور6-هیدروکسی دوپامین کشت داده شدند. نقش محافظتی آستاگزانتین با روش شمارش سلولیآبی تریپان ارزیابی شد.میزان زنده ماندن سلولهای SH-SY5Y با استفاده از روش MTT تعیین شد.
یافته ها : نتایج نشان داد که اختلالات رفتاری ناشی از 6-هیدروکسی دوپامین در موش ها توسط آستاگزانتینبهبود یافته است.انکوباسیون با آستاگزانتین آپوپتوز و نکروز سلول های SH-SY5Y ناشی از 6-هیدروکسی دوپامینرا مهار کرد. همچنین اختلال زنده ماندن سلول های SH-SY5Y توسط پیش درمانیبا آستاگزانتینترمیم شد.
نتیجه گیری: نتایج ما نشان داد که درمان با آستاگزانتینمی تواند از سلول های SH-SY5Y و نورون های دوپامینرژیک جسم سیاه در مقابل سمیت ناشی از 6-هیدروکسی دوپامینبه صورت وابسته به دوز محافظت کند.

کلیدواژه‌ها

عنوان مقاله [English]

In-vitro and in-vivo evaluation of the anti-Parkinson activity of Astaxanthin

نویسندگان [English]

  • Mahin mafyEsmaeili 1
  • maryam khosravi 2
  • Mohammad Hossein Esmaeili 3
  • Maryam Bananej 4
  • Jalal Solati 5
1 Student of animal physiology, Biology Department, Faculty of Biological Sciences, North Tehran Branch, Islamic Azad University, Tehran, Iran
2 Assistant professor of physiology Biology Department, Faculty of Biological Sciences, North Tehran Branch, Islamic Azad University, Tehran, Iran (Corresponding Author)
3 Professor of physiology, Department of Physiology , Qazvin University of Medical Sciences, Qazvin, Iran.
4 Assistant professor of physiology Biology Department , Faculty of Biological Sciences, , North Tehran Branch, Islamic Azad University, Tehran, Iran.
5 Assistant professor of physiology Biology Department , Faculty of Biological Sciences, , North Tehran Branch, Islamic Azad University, Tehran, Iran.
چکیده [English]

Background and AimInflammation and oxidative stress are implicated in the pathogenesis of Parkinson’s disease (PD). Astaxanthin (ASTX) have antioxidant, anti-inflammatory and neuroprotectiveeffects,therefor may be useful for treatment of PD.In the present study, we investigated the beneficial effects of ASTX against the toxicity of 6-hydroxydopamine (6-OHDA) in animal and cellular models.
Materials and Methods:NMRI male mice, were used in this study. Parkinsonism was induced by injection of 6-OHDA (5 μg/1μl in 0.2 % ascorbic acid-saline) into the left striatum. Parkinsonian mice divided to: the control and treatment groups. The treatment groups were administered orally with water or ASTX (10, 20, and 30mg/kg) for 28 days.The behavioral activities of mice were determined by apomorphine-induced rotational test. The Dopaminergic SH-SY5Y cells were cultured for 48 h with various concentrations of ASTX (1.25, 2.5, 5, 10, 20 μmol/L) in the presence or absence of 6-OHDA.The toxicity of 6-OHDA was evaluated by trypan blue assay. The viability of SH-SY5Y cells following 6-OHDA exposure were determined by MTT assay.
Results:The results demonstrated that 6-OHDA-induced PD-like behavioral impairments of mice were significantly improved by ASTX. Pre incubation of SH-SY5Y cellswith ASTX inhibits the 6-OHDA ‑induced apoptosis and necrosis. The impaired viability of 6-OHDA-injured SH-SY5Y cells were significantly restored by ASTX pretreatment.
Conclusion: Our results indicated that ASTX treatment could protect SH-SY5Y cells and dopaminergic neurons of substantianigra from 6-OHDA -Induced Toxicity in a dose-dependent manner.

کلیدواژه‌ها [English]

  • Parkinson's disease
  • 6-hydroxydopamine
  • Astaxanthin
  • Apomorphine-induced rotational behavioral test

مراجع

  1. G. DeMaagd, A. Philip, Parkinson’s disease and its management: part 1: disease entity, risk factors,
    pathophysiology, Clin. Present. Diagnosis P T 40 (2015) 504–532.
    2. Nagatsu T, Sawada M. Biochemistry of postmortem brains in Parkinson's disease: historical overview and
    future prospects. J Neural TransmSuppl 2007(72):113-20.
    3. T.R. Mhyre, J.T. Boyd, R.W. Hamill, K.A. Maguire-Zeiss, Parkinson’s disease, Subcell. Biochem. 65 (2012)
    389–455
    4. Zhang H, Tsao R. Dietary polyphenols, oxidative stress and antioxidant and anti-inflammatory effects.
    CurrOpin Food Sci 2016; 8: 33–42.
    5. Lai PKK, Chan JYW, Wu SB, Cheng L, Ho GKW, Lau CP, et al. Anti-inflammatory activities of an active
    fraction isolated from the root of AXT ragalusmembranaceus in RAW 264.7 macrophages. Phytother Res
    2014;28: 395–404.
    6. W. Olanow, A. Schapira, J. Obeso, Parkinson’s disease and other movement disorders, in: D. Longo, D. Kasper, J.
    Jameson, A. Fauci, S. Hauser, J. Loscalzo (Eds.), Harrison’s Principles of Internal Medicine, 19th ed., McGraw-Hill
    Medical, New York, 2015, pp. 2609–2625.
    7. Sofic E, Lange KW, Jellinger K, Riederer P. Reduced and oxidized glutathione in the substantia nigra of
    patients with Parkinson’s disease. NeurosciLett. 1992; 142:128–30.
    8. Smith, J. A., Das, A., Ray, S. K., &Banik, N. L. (2012). Role of proinflammatory cytokines released from
    microglia in neurodegenerative diseases. Brain Research Bulletin, 87(1), 10–20.
    9. Lanzillotta, A., Porrini, V., Bellucci, A., Benarese, M., Branca, C., Parrella, E., et al. (2015). NF-kappaB in
    innate neuroprotection and age-related neurodegenerative diseases. Front. Neurol. 6:98. doi:
    10.3389/fneur.2015.00098
    10. Koo, J. W., Russo, S. J., Ferguson, D., Nestler, E. J., and Duman, R. S. (2010). Nuclear factor-kappaB is a
    critical mediator of stress-impaired neurogenesis and depressive behavior. Proc. Natl. Acad. Sci. U.S.A. 107,
    2669–2674.
    11. Mo C, Wang L, Zhang J, Numazawa S, Tang H, Tang X, et al. The crosstalk between Nrf2 and AMPK signal
    pathways is important for the anti-inflammatory effect of berberine in LPS-stimulated macrophages and
    endotoxin-shocked mice. Antioxid Redox Signal 2014; 20:574–88.
    12. Sergio Davinelli , Luciano Saso , Floriana D'Angeli , Vittorio Calabrese , Mariano Intrieri , Giovanni
    Scapagnini . Astaxanthin as a Modulator of Nrf2, NF-κB, and Their Crosstalk: Molecular Mechanisms and
    Possible Clinical Applications. 2022 Jan 14;27(2):502. doi: 10.3390/molecules27020502.
    13. Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov
    2013;12: 931–47.
    14. Park J-H, Choi JW, Ju EJ, Pae AN, Park KD. Antioxidant and anti-inflammatory activities of a natural
    compound, Shizukahenriol, through Nrf2 activation.Molecules 2015;20:15989–6003.
    15. Bahn G, Jo DG. Therapeutic Approaches to Alzheimer's Disease Through Modulation of NRF2.
    Neuromolecular Med. 2019 Mar; 21(1):1-11.
    16. D. Standeart, E. Roberson, Treatment of central nervous system degenerative disorders, in: L. Brunton, B.
    Chabner, B. Knollmann (Eds.), Goodman & Gilman’s: The Pharmacological Basis of Therapeutics, 12th ed.,
    Mcgraw Hill Medical, New York, 2012, pp. 609–628.
    17. Yang Y, Kim B, Lee J-Y. AXTaxanthin structure, metabolism, and health benefits. J Hum Nutr Food Sci
    2013;1:1–1003.
    18. Lin Zhao , Xueshu Tao , Tao Song .Astaxanthin alleviates neuropathic pain by inhibiting the MAPKs and NFκB pathways. . 2021 Dec 5;912:174575. doi: 10.1016/j.ejphar.2021.174575. Epub 2021 Oct 18.
    19. Beth Grimmig, Lauren Daly, MeenaSubbarayan, Ched Hudson, Robert Williamson, Kevin Nash, Paula C.
    Bickford. AXTaxanthin is neuroprotective in an aged mouse model of Parkinson’s disease. Oncotarget, 2018,
    Vol. 9, (No. 12), pp: 10388-10401
    20. Ji X, Peng D, Zhang Y, Zhang J, Wang Y, Gao Y, Lu N, Tang P. AXTaxanthin improves cognitive
    performance in mice following mild traumatic brain injury. Brain Research. 2017; 1659:88–95.
    21. Zhang XS, Zhang X, Zhou ML, Zhou XM, Li N, Li W, Cong ZX, Sun Q, Zhuang Z, Wang CX, Shi JX.
    Amelioration of oxidative stress and protection against early brain injury by AXTaxanthin after experimental
    subarachnoid hemorrhage. J Neurosurg. 2014; 121:42–54.
    22. Al-Amin MM, Reza HM, Saadi HM, Mahmud W, Ibrahim AA, Alam MM, Kabir N, Saifullah AR, Tropa ST,
    Quddus AH. AXTaxanthin ameliorates aluminum chloride-induced spatial memory impairment and neuronal
    oxidative stress in mice. Eur J Pharmacol. 2016; 777:60–9.
  2. 23. Lu Y, Xie T, He XX, Mao ZF, Jia LJ, Wang WP, Zhen JL, Liu LM. AXTaxanthin rescues neuron loss and
    attenuates oxidative stress induced by amygdala kindling in adult rat hippocampus. Neuroscience Letters.
    2015; 597:49–53.
    24. Lee, D.-H.; Kim, C.-S.; Lee, Y.J. AXTaxanthin protects against MPTP/MPP+-induced mitochondrial
    dysfunction and ROS production in vivo and in vitro. Food Chem. Toxicol. 2011, 49, 271–280.
    25. Liu, X.; Shibata, T.; Hisaka, S.; Osawa, T. AXTaxanthin inhibits reactive oxygen species-mediated cellular
    toxicity in dopaminergic SH-SY5Y cells via mitochondria-targeted protective mechanism. Brain Res. 2009,
    1254, 18–27.
    26. Ikeda, Y.; Tsuji, S.; Satoh, A.; Ishikura, M.; Shirasawa, T.; Shimizu, T. Protective e_ects of AXTaxanthin on
    6-hydroxydopamine-induced apoptosis in human neuroblAXToma SH-SY5Y cells. J. Neurochem. 2008,
    107,1730–1740.
    27. Lee SJ, Bai SK, Lee KS, Namkoong S, Na HJ, Ha KS, et al. AXTaxanthin inhibits nitric oxide production and
    inflammatory gene expression by suppressing I(kappa)B kinase-dependent NF-kappaB activation. Mol Cells
    2003;16:97–105.
    28. Campoio TR, Oliveira FA,Otton R. Oxidative stress in human lymphocytes treated with fatty acid mixture:
    role of carotenoid AXTaxanthin. Toxicol In Vitro 2011;25: 1448–56.
    29. Santos SD, Cahu TB, Firmino GO, de CAXTro CC, Carvalho Jr LB, Bezerra RS, et al. Shrimp wAXTe extract
    and AXTaxanthin: rat alveolar macrophage, oxidative stressand inflammation. J Food Sci 2012; 7:H141–6.
    30. Barros MP, Marin DP, Bolin AP, de Cassia Santos Macedo R, Campoio TR, Fineto Jr C, et al. Combined
    AXTaxanthin and fish oil supplementation improves glutathione based redox balance in rat plasma and
    neutrophils. Chem Biol Interact 2012;197:58–67.
    31. [31] Saw CLL, Yang AY, Guo Y, Kong A-NT. AXTaxanthin and omega-3 fatty acids individually and in
    combination protect against oxidative stress via the Nrf2–ARE pathway. Food Chem Toxicol2013;62:869–75.
    32. Li Z, Dong X, Liu H, Chen X, Shi H, Fan Y, et al. AXTaxanthin protects ARPE-19 cells from oxidative stress
    via upregulation of Nrf2-regulated phase II enzymes through activation of PI3K/Akt. Mol Vis 2013;19:1656–
    66.
    33. Callie Farruggiaa, Mi-Bo Kima, MinkyungBaea, YoojinLeea, Tho X. Phama, Yue Yanga,
    MyungJooHanb,Young-Ki Parka, Ji-Young Lee.AXTaxanthin exerts anti-inflammatory and antioxidant effects
    in macrophages in NRF2-dependent and independent manners. Journal of Nutritional Biochemistry 62 (2018)
    202–209.
    34. R.M. Abdelsalam, M.M. Safar, Neuroprotective effects of vildagliptin in rat rotenone Parkinson’s disease
    model: role of RAGE-NFκB and Nrf2-antioxidant signaling pathways, J. Neurochem. 133 (2015) 700–707.
    35. G. DeMaagd, A. Philip, Parkinson’s disease and its management: part 1: disease entity, risk factors,
    pathophysiology, Clin. Present. Diagnosis P T 40 (2015) 504–532.
    36. Silva J, Alves C, Pinteus S, Mendes S, PedrosaR.Silva J, et al. Neuroprotective effects of seaweeds against 6-
    hydroxidopamine-induced cell death on an in vitro human neuroblastoma model. BMC Complement Altern
    Med. 2018 Feb 14;18(1):58.
    37. Yan H, Huang Z, Bai Q, Sheng Y, Hao Z, Wang Z and Ji L: Natural product andrographolide alleviated
    APAP‑induced liver fibrosis by activating Nrf2 antioxidant pathway. Toxicology 396‑397:1‑12, 2018.
    38. Mei-Ling Wang , Qing-Yuan Zhong , Bao-Qin Lin 2 , Yu-Hong Liu , Yan-Feng Huang , Yang Chen , Jie
    Yuan, Zi-Ren Su, Janis Ya-Xian Zhan . Andrographolide sodium bisulfate attenuates UV-induced
    photo-damage by activating the keap1/Nrf2 pathway and downregulating the NF-κB pathway in HaCaT
    keratinocytes. International journal of molecular medicine 45: 343-352, 2020.
    39. Herpers B, Wink S, Fredriksson L, Di Z, Hendriks G, Vrieling H, de Bont H and van de Water B: Activation
    of the Nrf2 response by intrinsic hepatotoxic drugs correlates with suppression of NF‑κB activation and
    sensitizes toward TNFα‑induced cytotoxicity. Arch Toxicol 90: 1163‑1179, 2016.
    40. Chiou YS, Huang QR, Ho CT, Wang YJ and Pan MH: Directly interact with Keap1 and LPS is involved in the
    anti‑inflammatory mechanisms of (‑)‑epicatechin‑3‑gallate in LPS‑induced macrophages and endotoxemia.
    Free RadicBiol Med 94: 1‑16, 2016.
    41. Liu GH, Qu J and Shen X: NF‑kappaB/p65 antagonizes Nrf2‑ARE pathway by depriving CBP from Nrf2 and
    facilitating recruitment of HDAC3 to MafK. BiochimBiophysActa 1783: 713‑727, 2008.
    42. Pan H, Wang H, Wang X, Zhu L and Mao L: The absence of Nrf2 enhances NF‑κB‑dependent inflammation
    following scratch injury in mouse primary cultured astrocytes. Mediators Inflamm 2012: 217580, 2012.
    43. Cheung KL and Kong AN: Molecular targets of dietary phenethylisothiocyanate and sulforaphane for cancer
    chemoprevention.AAPS J 12: 87‑97, 2010.

مجله دانشکده پزشکی دانشگاه علوم پزشکی مشهد
دوره 65، شماره 3
مرداد-شهریور1401
مرداد و شهریور 1401
صفحه 1387-1400

فایل ها

هم رسانی

ارجاع به این مقاله

آمار